Sol-Gel Technologies Ltd. (SLGL): Price and Financial Metrics
GET POWR RATINGS... FREE!
SLGL POWR Grades
- Sentiment is the dimension where SLGL ranks best; there it ranks ahead of 96.2% of US stocks.
- SLGL's strongest trending metric is Momentum; it's been moving down over the last 206 days.
- SLGL's current lowest rank is in the Momentum metric (where it is better than 11.51% of US stocks).
SLGL Stock Summary
- The ratio of debt to operating expenses for Sol-Gel Technologies Ltd is higher than it is for about merely 8.65% of US stocks.
- With a price/sales ratio of 30.03, Sol-Gel Technologies Ltd has a higher such ratio than 93.03% of stocks in our set.
- Revenue growth over the past 12 months for Sol-Gel Technologies Ltd comes in at -61.7%, a number that bests only 4.82% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Sol-Gel Technologies Ltd are SEAC, SRTS, INTZ, UTSI, and KMDA.
- SLGL's SEC filings can be seen here. And to visit Sol-Gel Technologies Ltd's official web site, go to www.sol-gel.com.
SLGL Stock Price Chart Interactive Chart >
SLGL Price/Volume Stats
|Current price||$12.00||52-week high||$16.69|
|Prev. close||$12.11||52-week low||$7.00|
|Day high||$14.50||Avg. volume||50,889|
|50-day MA||$11.46||Dividend yield||N/A|
|200-day MA||$10.46||Market Cap||244.68M|
Sol-Gel Technologies Ltd. (SLGL) Company Bio
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea; and TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris. It is also involved in the development of generic dermatological candidates; and formulation and pre-clinical development of early stage product candidates for acne and rosacea, and other dermatological indications. The company was founded in 1997 and is based in Ness Ziona, Israel
SLGL Latest News Stream
|Loading, please wait...|
SLGL Latest Social Stream
View Full SLGL Social Stream
Latest SLGL News From Around the Web
Below are the latest news stories about Sol-Gel Technologies Ltd that investors may wish to consider to help them evaluate SLGL as an investment opportunity.
NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET. About Sol-Gel Technologies Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded a
Sol-Gel investigational SGT-510 was found to be more effective than roflumilast cream, 0.3%, in a human xenograft psoriasis animal modelSol-Gel is developing tapinarof cream, 1%, aiming to offer product formulation innovations and increased affordability for patients compared to the brand expected to be launchedOur proof-of-concept study for SGT-210 (erlotinib gel) in palmoplantar keratoderma patients has been completed and indicated a possible modest improvementSol-Gel to host Conference Call t
Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States
NESS ZIONA, Israel & LAUSANNE, Switzerland, June 28, 2021--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology company, today announced they have signed two exclusive 5-year license agreements for the commercialization of EPSOLAY® and TWYNEO® in the United States.
Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference
NESS ZIONA, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will present a Company overview and business update at the following upcoming virtual investor conferences: Jefferies Healthcare Conference (June 1 – 4, 2021)Speaker:Dr. Alon Seri-Levy, Chief Executive OfficerDate:Tuesday, June 1, 2021Time:8:30 – 8:55 am EDT Raymond James Human Health Innovation Conference (June 21 – 23, 2021)Speaker:Dr. Alon Seri-Levy, Chief Executive OfficerDate:Tuesday, June 22, 2021Time:10:00 – 10:30 am EDT A recording of the webcast of each presentation will ...
In a recent note on the state of the stock markets, Raymond James equity strategist Tavis McCourt points out a series of policy factors that are playing a role in the current market volatility; the situation is more complex, perhaps, than most of us have been willing to admit. McCourt notes permutations of the SLR rule, political dynamics on the Senate Banking Committee, and the regulatory atmosphere towards potential capital return are all influencing the Fed’s moves and the market reactions.
SLGL Price Returns
Continue Researching SLGLWant to see what other sources are saying about Sol-Gel Technologies Ltd's financials and stock price? Try the links below:
Sol-Gel Technologies Ltd (SLGL) Stock Price | Nasdaq
Sol-Gel Technologies Ltd (SLGL) Stock Quote, History and News - Yahoo Finance
Sol-Gel Technologies Ltd (SLGL) Stock Price and Basic Information | MarketWatch